Natural products like curcumin (104) can likewise reduce lactylation by inhibiting p300 activity and have shown anti-inflammatory and anti-tumor efficacy in animal studies, yet their low selectivity and unfavorable pharmacokinetic profiles remain the principal obstacles to clinical translation. Here, EP300 is linked to neoplasm.